Bavarian Nordic A/S

$30.87+1.91%(+$0.58)
TickerSpark Score
78/100
Solid
80
Valuation
85
Profitability
80
Growth
96
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVNKF research report →

52-Week Range42% of range
Low $26.08
Current $30.87
High $37.60

Companywww.bavarian-nordic.com

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers.

CEO
Paul John Chaplin
IPO
2010
Employees
1,645
HQ
Hellerup, DK

Price Chart

+15.19% · this period
$37.60$31.90$26.20May 20Nov 18May 20

Valuation

Market Cap
$2.38B
P/E
12.97
P/S
2.57
P/B
1.20
EV/EBITDA
6.53
Div Yield
0.00%

Profitability

Gross Margin
47.40%
Op Margin
25.36%
Net Margin
19.83%
ROE
9.25%
ROIC
8.35%

Growth & Income

Revenue
$6.16B · 7.71%
Net Income
$1.37B · 38.90%
EPS
$17.61 · 39.76%
Op Income
$918.69M
FCF YoY
857.65%

Performance & Tape

52W High
$37.60
52W Low
$26.08
50D MA
$30.03
200D MA
$32.33
Beta
0.95
Avg Volume
150

Get TickerSpark's AI analysis on BVNKF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Our BVNKF Coverage

We haven't published any research on BVNKF yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate BVNKF Report →

Similar Companies